Pharsight

Xatmep patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116724 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US10231927 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US10610485 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US9855215 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US9259427 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

Xatmep is owned by Azurity.

Xatmep contains Methotrexate Sodium.

Xatmep has a total of 5 drug patents out of which 0 drug patents have expired.

Xatmep was authorised for market use on 25 April, 2017.

Xatmep is available in solution;oral dosage forms.

Xatmep can be used as treatment of juvenile rheumatoid arthritis, a method for treating acute lymphoblastic leukemia.

The generics of Xatmep are possible to be released after 02 January, 2033.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-137) Apr 25, 2024
Orphan Drug Exclusivity(ODE-138) Apr 25, 2024
Orphan Drug Exclusivity(ODE) Apr 25, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using METHOTREXATE SODIUM ingredient

Market Authorisation Date: 25 April, 2017

Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis

Dosage: SOLUTION;ORAL

More Information on Dosage

XATMEP family patents

Family Patents